Mark Laughlin
7Patents
4h-index
14Co-inventors
46Inventor score
Filing activity: May 1, 2000 → Mar 26, 2008
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6689765B2 | Piperazine derivatives useful as CCR5 antagonists | Chemistry; Metallurgy | 49 | Expired |
| US6387930B1 | Piperidine derivatives useful as CCR5 antagonists | Chemistry; Metallurgy | 34 | Expired |
| US6635646B1 | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy | Human Necessities | 14 | Expired |
| US6602885B2 | Piperidine derivatives useful as CCR5 antagonists | Chemistry; Metallurgy | 7 | Expired |
| US7384944B2 | Piperazine derivatives useful as CCR5 antagonists | Chemistry; Metallurgy | 3 | Expired |
| US8114879B2 | Piperazine derivatives useful as CCR5 antagonists | Chemistry; Metallurgy | 0 | Active |
| US7247631B2 | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.